AstraZeneca (HAM:ZEG) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


HAM:ZEG AstraZeneca PLC HAM:ZEG
87 GF Score
Price €163.40
GF Value €155.73
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AstraZeneca's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

HAM:ZEG vs LLY, JNJ, ABBV: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Margin of Safety % (DCF FCF Based) falls into.


HAM:ZEG
87GF Score
AstraZeneca PLC HAM:ZEG
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (HAM:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of €163.40 is trading 4.9% above its estimated GF Value™ of €155.73. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for HAM:ZEG:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €155.73 vs. price of €163.40 (4.9% above fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the HAM:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score

Get the complete analysis for HAM:ZEG

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€163.40
Price
€155.73
GF Value